Page last updated: 2024-10-16

carnitine and Ischemia

carnitine has been researched along with Ischemia in 33 studies

Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Research Excerpts

ExcerptRelevanceReference
" Propionyl-L-carnitine (PLC) is efficacious in improving pain free walking distance in peripheral arterial disease with claudication; it also exerts favorable effects on the arterial wall and on endothelial function."9.16Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. ( Arosio, E; De Marchi, S; Fondrieschi, L; Prior, M; Rigoni, A; Rulfo, F; Scuro, A; Zecchetto, S, 2012)
"To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines."9.14Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."7.81Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"To investigate the protective effects of L-carnitine upon testicular ischemia-reperfusion injury in rats."7.75[Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats]. ( Guan, Y; Li, SW; Yang, ZW; Zheng, XM, 2009)
"The study aimed to examine whether L-carnitine and its derivatives, acetyl-L-carnitine and propionyl-L-carnitine, were equally effective and able to improve postischemic cardiac function, reduce the incidence of reperfusion-induced ventricular fibrillation, infarct size, and apoptotic cell death in ischemic/reperfused isolated rat hearts."7.72Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. ( Bertelli, A; Cui, J; Das, DK; Tosaki, A, 2003)
"The present study was designed to examine whether propionyl-l-carnitine, an acyl derivative of carnitine involved in fatty acid oxidation pathway and adenosine 5'-triphosphate (ATP) generation of mitochondria, prevented renal function deterioration and structural injury induced by ischemia-reperfusion in an ex vivo rat model of isolated perfused kidney (IPK) preparation and in vivo in a model of syngeneic kidney transplantation."7.71Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. ( Abbate, M; Aiello, S; Arduini, A; Azzollini, N; Gagliardini, E; Mister, M; Noris, M; Perico, N; Remuzzi, G; Szymczuk, J; Trochimowicz, L, 2002)
"In this study we have examined the effect of propionyl-L-carnitine (PC) on rat spinal cord ischaemia and post-ischaemic reperfusion injury by evaluating two lipid peroxidation indices, thiobarbituric acid reactive substances (TBARS) and diene conjugation, before and after the addition of an ADP-Fe+2 complex to spinal cord homogenates."7.68Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury. ( Arduini, A; Belfiglio, M; Di Toppi, GS; Federici, G; Fernandez, E; Mancinelli, G; Pallini, R; Scurti, R, 1990)
"L-carnitine treatment reduced these parameters to the values of sham operated rats."5.32L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation. ( Agac, A; Aliciguzel, Y; Demir, N; Derin, N; Izgut-Uysal, VN, 2004)
" Propionyl-L-carnitine (PLC) is efficacious in improving pain free walking distance in peripheral arterial disease with claudication; it also exerts favorable effects on the arterial wall and on endothelial function."5.16Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. ( Arosio, E; De Marchi, S; Fondrieschi, L; Prior, M; Rigoni, A; Rulfo, F; Scuro, A; Zecchetto, S, 2012)
"To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines."5.14Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009)
"Propionyl-L-carnitine (PrC) has been shown to exert beneficial effects in the treatment of myocardial and peripheral ischemia in man."5.09Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine. ( Battaglia, C; Brevetti, G; Gentile, M; Golino, P; Marone, G; Oriente, A; Triggiani, M, 1999)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."3.81Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"To investigate the protective effects of L-carnitine upon testicular ischemia-reperfusion injury in rats."3.75[Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats]. ( Guan, Y; Li, SW; Yang, ZW; Zheng, XM, 2009)
"Carnitine has a positive effect in such a model, particularly in preventing the progressive effect of burn, and limiting the necrosis in the full-thickness burned part."3.72The effects of carnitine on distally-burned dorsal skin flap: an experimental study in rats. ( Aksoy, A; Arslan, E; Bagdatoglu, O; Demirkan, F; Milcan, A; Polat, A; Polat, G; Unal, S, 2003)
"The study aimed to examine whether L-carnitine and its derivatives, acetyl-L-carnitine and propionyl-L-carnitine, were equally effective and able to improve postischemic cardiac function, reduce the incidence of reperfusion-induced ventricular fibrillation, infarct size, and apoptotic cell death in ischemic/reperfused isolated rat hearts."3.72Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. ( Bertelli, A; Cui, J; Das, DK; Tosaki, A, 2003)
"L-carnitine represents a feasible metabolic adjunct for a safe and more successful preservation of ischemia-reperfusion-sensitive steatotic livers."3.72L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation. ( Decker, D; Dombrowski, F; Lauschke, H; Pütz, U; Tolba, RH, 2003)
" We investigated whether sodium bicarbonate-induced metabolic alkalosis could positively affect force development during the rest-to-work transition in ischaemic skeletal muscle."3.71Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle. ( Constantin-Teodosiu, D; Greenhaff, PL; Loxham, SJ; Poucher, SM; Roberts, PA, 2002)
"The present study was designed to examine whether propionyl-l-carnitine, an acyl derivative of carnitine involved in fatty acid oxidation pathway and adenosine 5'-triphosphate (ATP) generation of mitochondria, prevented renal function deterioration and structural injury induced by ischemia-reperfusion in an ex vivo rat model of isolated perfused kidney (IPK) preparation and in vivo in a model of syngeneic kidney transplantation."3.71Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. ( Abbate, M; Aiello, S; Arduini, A; Azzollini, N; Gagliardini, E; Mister, M; Noris, M; Perico, N; Remuzzi, G; Szymczuk, J; Trochimowicz, L, 2002)
"We have characterized the effects of hypoxia on carnitine metabolism in proximal tubules."3.69Hypoxia-induced amphiphiles inhibit renal Na+, K(+)-ATPase. ( Bertorello, AM; Creer, MH; Mandel, LJ; Noble, S; Portilla, D; Schonefeld, M, 1996)
"In this study we have examined the effect of propionyl-L-carnitine (PC) on rat spinal cord ischaemia and post-ischaemic reperfusion injury by evaluating two lipid peroxidation indices, thiobarbituric acid reactive substances (TBARS) and diene conjugation, before and after the addition of an ADP-Fe+2 complex to spinal cord homogenates."3.68Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury. ( Arduini, A; Belfiglio, M; Di Toppi, GS; Federici, G; Fernandez, E; Mancinelli, G; Pallini, R; Scurti, R, 1990)
"Carnitine is an endogenous cofactor, having a regulatory action on the energy flow from different oxidative sources."1.38Comparing the effect between oral and injection form of carnitine on skin flap survival in rats. ( Lawanlakkana, P; Pitiseree, A; Saraithong, S; Suwantemee, C, 2012)
"L-carnitine treatment reduced these parameters to the values of sham operated rats."1.32L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation. ( Agac, A; Aliciguzel, Y; Demir, N; Derin, N; Izgut-Uysal, VN, 2004)
"Carnitine is an endogenous cofactor, for having a regulatory action on the energy flow from different oxidative sources."1.32Dual synergistic effect: the effect of dexamethasone plus carnitine on skin flap survival. ( Babuccu, O; Deren, O; Erdogan, B; Hosnuter, M; Kargi, E, 2004)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19902 (6.06)18.7374
1990's11 (33.33)18.2507
2000's13 (39.39)29.6817
2010's6 (18.18)24.3611
2020's1 (3.03)2.80

Authors

AuthorsStudies
Liepinsh, E1
Kuka, J1
Vilks, K1
Svalbe, B1
Stelfa, G1
Vilskersts, R1
Sevostjanovs, E1
Goldins, NR1
Groma, V1
Grinberga, S1
Plaas, M1
Makrecka-Kuka, M1
Dambrova, M1
Moghaddas, A1
Dashti-Khavidaki, S1
Shiga, T1
Sahara, H1
Orito, K1
Milio, G1
Novo, G1
Genova, C1
Luigi Almasio, P1
Novo, S1
Pinto, A1
Guan, Y1
Zheng, XM1
Yang, ZW1
Li, SW1
Stasi, MA1
Scioli, MG1
Arcuri, G1
Mattera, GG1
Lombardo, K1
Marcellini, M1
Riccioni, T1
De Falco, S1
Pisano, C1
Spagnoli, LG1
Borsini, F1
Orlandi, A1
Riccioni, C1
Sarcinella, R1
Izzo, A1
Palermo, G1
Liguori, M1
Caliumi, C1
Carloni, E1
Paolucci, AM1
D'andrea, P1
Pompili, S1
Lawanlakkana, P1
Saraithong, S1
Suwantemee, C1
Pitiseree, A1
De Marchi, S1
Zecchetto, S1
Rigoni, A1
Prior, M1
Fondrieschi, L1
Scuro, A1
Rulfo, F1
Arosio, E1
Roberts, PA2
Loxham, SJ2
Poucher, SM3
Constantin-Teodosiu, D3
Greenhaff, PL3
Arslan, E1
Milcan, A1
Unal, S1
Demirkan, F1
Polat, A1
Bagdatoglu, O1
Aksoy, A1
Polat, G1
Cui, J1
Das, DK1
Bertelli, A1
Tosaki, A1
Tolba, RH2
Pütz, U1
Decker, D1
Dombrowski, F2
Lauschke, H1
Hiatt, WR1
Derin, N1
Izgut-Uysal, VN1
Agac, A1
Aliciguzel, Y1
Demir, N1
Kargi, E1
Deren, O1
Babuccu, O1
Hosnuter, M1
Erdogan, B1
Vavilin, VA1
Filippova, SN1
Panov, AV1
Levandovskiĭ, IV1
Stevens, MJ1
Feldman, EL1
Greene, DA1
Corsi, C1
Pollastri, M1
Marrapodi, E1
Leanza, D1
Giordano, S1
D'Iddio, S1
Peschechera, A1
Ferrari, LE1
Arrigoni-Martelli, E1
Hülsmann, WC1
Timmons, JA1
Worrall, V1
Macdonald, IA1
Schonefeld, M1
Noble, S1
Bertorello, AM1
Mandel, LJ1
Creer, MH1
Portilla, D1
Nagai, M1
Watanabe, M1
Endoh, M1
Danbara, H1
Triggiani, M1
Oriente, A1
Golino, P1
Gentile, M1
Battaglia, C1
Brevetti, G3
Marone, G1
Scarpini, E1
Doneda, P1
Pizzul, S1
Chiodi, P1
Ramacci, MT1
Baron, P1
Conti, G1
Sacilotto, G1
Arduini, A3
Scarlato, G1
Puetz, U1
Akbar, S1
Minor, T1
Signorelli, SS1
Malaponte, G1
Di Pino, L1
Digrandi, D1
Pennisi, G1
Mazzarino, MC1
Mister, M1
Noris, M1
Szymczuk, J1
Azzollini, N1
Aiello, S1
Abbate, M1
Trochimowicz, L1
Gagliardini, E1
Perico, N1
Remuzzi, G1
Perna, S2
Sabbà, C1
Rossini, A1
Scotto di Uccio, V1
Berardi, E1
Godi, L1
Angelini, C1
Rosa, M1
Carrozzo, R1
Corsi, M1
Matarazzo, A1
Marcialis, A1
Fernandez, E1
Pallini, R1
Mancinelli, G1
Di Toppi, GS1
Belfiglio, M1
Scurti, R1
Federici, G1
Pauly, DF1
Yoon, SB1
McMillin, JB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]Phase 4164 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Claudication Onset Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.065
Cilostazol + Placebo0.896

Change From Baseline in Claudication Onset Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.001
Cilostazol + Placebo0.815

Change From Baseline in Peak Walking Time (PWT) at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.241
Cilostazol + Placebo0.134

Change From Baseline in Peak Walking Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.267
Cilostazol + Placebo0.145

Change From Baseline in Peak Walking Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.166
Cilostazol + Placebo0.139

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine13.20
Cilostazol + Placebo6.57

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine12.98
Cilostazol + Placebo10.01

Reviews

3 reviews available for carnitine and Ischemia

ArticleYear
L-Carnitine and Potential Protective Effects Against Ischemia-Reperfusion Injury in Noncardiac Organs: From Experimental Data to Potential Clinical Applications.
    Journal of dietary supplements, 2018, Sep-03, Volume: 15, Issue:5

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Female; Gastrointestinal Diseases; Human

2018
Treatment of disability in peripheral arterial disease: new drugs.
    Current drug targets. Cardiovascular & haematological disorders, 2004, Volume: 4, Issue:3

    Topics: Arteriosclerosis; Carnitine; Clinical Trials as Topic; Exercise Therapy; Humans; Hypolipidemic Agent

2004
The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects.
    Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:7

    Topics: Aldehyde Reductase; Animals; Carnitine; Cells; Diabetes Mellitus; Diabetes Mellitus, Experimental; D

1995

Trials

6 trials available for carnitine and Ischemia

ArticleYear
Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
    Cardiovascular drugs and therapy, 2009, Volume: 23, Issue:4

    Topics: Aged; Alprostadil; Cardiotonic Agents; Carnitine; Chronic Disease; Double-Blind Method; Drug Synergi

2009
Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Monitoring, Transcutaneo

2012
L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease.
    Angiology, 1995, Volume: 46, Issue:8

    Topics: Aged; Blood Flow Velocity; Carnitine; Cross-Over Studies; Double-Blind Method; Humans; Hyperemia; In

1995
Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine.
    Biochemical pharmacology, 1999, Oct-15, Volume: 58, Issue:8

    Topics: Adult; Arachidonic Acids; Blood Platelets; Cardiotonic Agents; Carnitine; Eicosanoids; Humans; In Vi

1999
Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration.
    Pharmacological research, 2001, Volume: 44, Issue:4

    Topics: Aged; Arteriosclerosis; Cardiotonic Agents; Carnitine; Cell Adhesion Molecules; Chronic Disease; E-S

2001
Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study.
    European heart journal, 1992, Volume: 13, Issue:2

    Topics: Arterial Occlusive Diseases; Carnitine; Dose-Response Relationship, Drug; Double-Blind Method; Exerc

1992

Other Studies

24 other studies available for carnitine and Ischemia

ArticleYear
Low cardiac content of long-chain acylcarnitines in TMLHE knockout mice prevents ischaemia-reperfusion-induced mitochondrial and cardiac damage.
    Free radical biology & medicine, 2021, Volume: 177

    Topics: Animals; Carnitine; Ischemia; Male; Mice; Mice, Knockout; Mitochondria, Heart; Reperfusion

2021
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
    Pharmacology, 2015, Volume: 96, Issue:5-6

    Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati

2015
[Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats].
    Zhonghua yi xue za zhi, 2009, Jul-14, Volume: 89, Issue:26

    Topics: Animals; Apoptosis; Carnitine; Heat-Shock Proteins; Ischemia; Male; Rats; Rats, Sprague-Dawley; Repe

2009
Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Carnitine; Cell Proliferation; Chic

2010
Rehabilitative treatment in peripheral artery disease: protocol application and follow-up.
    Minerva cardioangiologica, 2010, Volume: 58, Issue:5

    Topics: Aged; Cardiotonic Agents; Carnitine; Clinical Protocols; Combined Modality Therapy; Diabetes Mellitu

2010
Comparing the effect between oral and injection form of carnitine on skin flap survival in rats.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95 Suppl 5

    Topics: Administration, Oral; Analysis of Variance; Animals; Carnitine; Case-Control Studies; Graft Survival

2012
The acetyl group deficit at the onset of contraction in ischaemic canine skeletal muscle.
    The Journal of physiology, 2002, 10-15, Volume: 544, Issue:2

    Topics: Acetyl Coenzyme A; Acetylation; Animals; Carnitine; Coenzyme A; Dogs; Enzyme Activation; In Vitro Te

2002
Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle.
    Experimental physiology, 2002, Volume: 87, Issue:4

    Topics: Acetylcarnitine; Alkalosis; Animals; Carnitine; Dogs; Electric Stimulation; Female; Infusions, Intra

2002
The effects of carnitine on distally-burned dorsal skin flap: an experimental study in rats.
    Burns : journal of the International Society for Burn Injuries, 2003, Volume: 29, Issue:3

    Topics: Acetylcholinesterase; Animals; Burns; Carnitine; Ischemia; Malondialdehyde; Necrosis; Nitric Oxide;

2003
Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts.
    Molecular and cellular biochemistry, 2003, Volume: 254, Issue:1-2

    Topics: Acetylcarnitine; Animals; Apoptosis; Cardiotonic Agents; Carnitine; Heart; Ischemia; Myocardium; Myo

2003
L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation.
    Transplantation, 2003, Dec-27, Volume: 76, Issue:12

    Topics: Alanine Transaminase; Animals; Carnitine; Fatty Liver; Glucose; Glutamate Dehydrogenase; Ischemia; L

2003
L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2004, Volume: 55, Issue:3

    Topics: Animals; Carnitine; Catalase; Dinoprostone; Gastric Mucosa; Glutathione Peroxidase; Glycosaminoglyca

2004
Dual synergistic effect: the effect of dexamethasone plus carnitine on skin flap survival.
    Annals of plastic surgery, 2004, Volume: 53, Issue:5

    Topics: Animals; Carnitine; Dexamethasone; Drug Synergism; Ischemia; Rats; Rats, Sprague-Dawley; Surgical Fl

2004
[Mechanisms of disruption of mitochondrial transport of adenine nucleotides in the course of acute hepatic ischemia].
    Biulleten' eksperimental'noi biologii i meditsiny, 1980, Volume: 89, Issue:4

    Topics: Acute Disease; Acyl Coenzyme A; Adenine Nucleotides; Animals; Carnitine; Female; Ischemia; Ketogluta

1980
Uptake and release of carnitine by vascular endothelium in culture; effects of protons and oxygen free radicals.
    Molecular and cellular biochemistry, 1995, Jan-26, Volume: 142, Issue:2

    Topics: Acidosis; Animals; Carnitine; Cattle; Cell Membrane; Cells, Cultured; Endothelium, Vascular; Female;

1995
Increased acetyl group availability enhances contractile function of canine skeletal muscle during ischemia.
    The Journal of clinical investigation, 1996, Feb-01, Volume: 97, Issue:3

    Topics: Acetylcarnitine; Adenosine Triphosphate; Aerobiosis; Anaerobiosis; Animals; Carbohydrate Metabolism;

1996
Hypoxia-induced amphiphiles inhibit renal Na+, K(+)-ATPase.
    Kidney international, 1996, Volume: 49, Issue:5

    Topics: Animals; Carnitine; Dogs; Fatty Acids; Hypoxia; In Vitro Techniques; Ischemia; Kidney; Kidney Tubule

1996
Inhibitory effect of acyl-CoA and acyl-carnitine compounds on the ischemia-inducing activity of Bordetella heat-labile toxin in guinea pig skin.
    Biological & pharmaceutical bulletin, 1997, Volume: 20, Issue:2

    Topics: Acyl Coenzyme A; Animals; Bacterial Toxins; Bordetella; Carnitine; Fatty Acids, Unsaturated; Guinea

1997
L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects.
    Journal of the peripheral nervous system : JPNS, 1996, Volume: 1, Issue:2

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Carnitine; Diabetic Neuropathies; Female; Humans; I

1996
Effects of L-carnitine-hydrochloride in the cold ischemic preservation of fatty liver grafts.
    Transplantation proceedings, 2001, Volume: 33, Issue:4

    Topics: Animals; Carnitine; Cold Temperature; Fatty Liver; Glucose; Ischemia; L-Lactate Dehydrogenase; Liver

2001
Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion.
    Kidney international, 2002, Volume: 61, Issue:3

    Topics: Animals; Carnitine; In Vitro Techniques; Ischemia; Kidney; Kidney Transplantation; Male; Rats; Rats,

2002
Muscle carnitine deficiency in patients with severe peripheral vascular disease.
    Circulation, 1991, Volume: 84, Issue:4

    Topics: Aged; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Humans; Ischemia;

1991
Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury.
    Free radical research communications, 1990, Volume: 10, Issue:6

    Topics: Animals; Carnitine; Free Radicals; In Vitro Techniques; Ischemia; Lipid Peroxidation; Male; Rats; Ra

1990
Carnitine-acylcarnitine translocase in ischemia: evidence for sulfhydryl modification.
    The American journal of physiology, 1987, Volume: 253, Issue:6 Pt 2

    Topics: Animals; Biological Transport; Carnitine; Carnitine Acyltransferases; Carnitine O-Palmitoyltransfera

1987